Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa.

Ketty Peris, Alfredo Piccerillo, May El Hachem, Vito R De, Luca EV De

Risultato della ricerca: Contributo in rivistaArticolo in rivista

3 Citazioni (Scopus)

Abstract

Immunomodulating agents such as anti–programmed cell death protein 1 (PD-1) have recently gained a crucial role in the treatment of numerous human malignant tumors.1 Cemiplimab is a novel PD-1 blocker approved for the treatment of locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC) in patients who are not candidates for curative surgery or radiation.2 During the last few years, other anti–PD-1 agents such as pembrolizumab and nivolumab have occasionally been used off-label to manage cases of advanced cSCC.3 We describe 1 patient with recessive dystrophic epidermolysis bullosa (RDEB) and multiple cSCCs who was successfully treated with pembrolizumab.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaJAMA Dermatology
Volume2020
Stato di pubblicazionePubblicato - 2020

Keywords

  • Pembrolizumab
  • distrophyc epidermolisis bullosa
  • multiple SCC

Fingerprint Entra nei temi di ricerca di 'Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa.'. Insieme formano una fingerprint unica.

Cita questo